Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 69452-156

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 69452-156). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc.,, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 01

A line graph showing the estimated probability of response over time (hours post-dose) comparing placebo, rizatriptan benzoate tablets 5 mg, and rizatriptan benzoate tablets 10 mg. The graph illustrates increasing response probabilities, with higher doses showing greater response rates over a 2-hour period.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 02

A line graph depicting the estimated probability of remediation or rescue over 24 hours post-dose for rizatriptan benzoate tablets at 5 mg and 10 mg doses compared with placebo. The x-axis represents hours post-dose from 0 to 24, and the y-axis shows the estimated probability from 0% to 100%. Three lines represent placebo, 5 mg tablets, and 10 mg tablets, showing different rates of effectiveness over time.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 03

A line graph depicting the estimated probability of response over time (hours post-dose) for rizatriptan benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph shows increased response probability with higher doses and time after administration.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 04

A Kaplan-Meier curve showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo and rizatriptan benzoate orally disintegrating tablets at 5 mg and 10 mg doses. The graph's x-axis represents hours post-dose, and the y-axis represents the probability percentage from 0% to 100%. The 10 mg dose shows a higher probability curve compared to the 5 mg dose and placebo.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 05

A line graph comparing the percentage response over time for Rizatriptan Benzoate Orally Disintegrating Tablets versus placebo. The x-axis shows hours post second dose (0.5 to 2.0 hours), and the y-axis shows percent response with confidence intervals. Rizatriptan shows higher percent response than placebo at each time point.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 06

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg in peelable lidding foil blister packs. The label includes lot and expiration space, barcode, manufacturer details showing Panacea Biotec Pharma Ltd. India and distributor Bionpharma Inc. USA. The label is designed with black and Pantone 300C blue colors, specifying foil width and blister size for the USA market.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 07

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg carton label displays the product name prominently along with strength 5 mg. The label is for 18 unit-dose tablets (six blisters of 3 unit-dose each), distributed by Bionpharma Inc. The packaging includes directions for removing tablets, manufacturing information from Panacea Biotec Pharma Limited, and barcode with NDC 69452-156-73.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 08

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg peelable lidding foil packaging label. The label displays multiple barcodes and product information, including the active ingredient rizatriptan benzoate equivalent to 10 mg rizatriptan base. Manufactured by Panacea Biotec Pharma Ltd. and distributed by Bionpharma Inc., USA. The label includes spaces for lot and expiration coding and uses black and Pantone 1375 C colors.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 09

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg by Bionpharma Inc. The label includes dosage form as orally disintegrating tablets, strength 10 mg, and packaging in 18 unit-doses (6 blisters of 3 unit-dose each). The label displays NDC 69452-157-73 and provides manufacturer information as Panacea Biotec Pharma Limited, India, with distribution by Bionpharma Inc., USA. It also shows handling and storage instructions, along with peel-off and alternative opening methods for blister packs.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 88 1

Chemical structure of rizatriptan benzoate, showing the molecular arrangement of the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.